(Q40694333)

22 September 2017

1 reference

title

Etoposide: current status and future perspectives in the management of malignant neoplasms (English)

1 reference

22 September 2017

1 reference

Belani CP

1

1 reference

22 September 2017

Doyle LA

series ordinal

2

1 reference

22 September 2017

Aisner J

series ordinal

3

1 reference

22 September 2017

publication date

1 January 1994

1 reference

Cancer Chemotherapy and Pharmacology

22 September 2017

published in

1 reference

22 September 2017

volume

34 Suppl

1 reference

22 September 2017

page(s)

S118-26

1 reference

Multidrug resistance (mdr) genes in human cancer

22 September 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF00684875

Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate.

21 January 2018

1 reference

12 December 2020

Etoposide in the management of non-small cell lung cancer

1 reference

12 December 2020

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

12 December 2020

Total lymphoid irradiation, high-dose chemotherapy and autologous bone marrow transplantation for chemotherapy-resistant Hodgkin's disease

1 reference

12 December 2020

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer

1 reference

12 December 2020

Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation

1 reference

12 December 2020

ProMACE-cytaBOM versus MACOP-B in intermediate and high grade NHL. Preliminary results of a prospective randomized trial

1 reference

12 December 2020

Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease

1 reference

12 December 2020

Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide

1 reference

12 December 2020

Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study

1 reference

12 December 2020

Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol

1 reference

12 December 2020

Bioavailability and pharmacokinetics of etoposide (VP-16)

1 reference

12 December 2020

Twenty years of MOPP therapy for Hodgkin's disease

1 reference

12 December 2020

Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Etoposide in the treatment of leukemias

1 reference

12 December 2020

Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation

1 reference

12 December 2020

Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial

1 reference

12 December 2020

VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules

1 reference

12 December 2020

Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy

1 reference

12 December 2020

Treatment of advanced resistant Hodgkin's disease with lomustine, etoposide, and prednimustine.

1 reference

12 December 2020

Single-agent oral etoposide for elderly small cell lung cancer patients.

1 reference

12 December 2020

Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation

1 reference

12 December 2020

Expression of a multidrug resistance gene in human cancers

1 reference

12 December 2020

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer

1 reference

12 December 2020

Induction failures in childhood acute nonlymphocytic leukemia: etoposide/5-azacytidine for cases refractory to daunorubicin/cytarabine

1 reference

12 December 2020

Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial

1 reference

12 December 2020

Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection?

1 reference

12 December 2020

Interaction of recombinant human tumor necrosis factor and etoposide in human lung cancer cell lines.

1 reference

12 December 2020

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance

1 reference

12 December 2020

Effective remission induction of refractory childhood acute nonlymphocytic leukemia by VP-16-213 plus azacitidine

1 reference

12 December 2020

Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

1 reference

12 December 2020

Preclinical leads for innovative uses for etoposide

1 reference

12 December 2020

Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia.

1 reference

12 December 2020

Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance

1 reference

12 December 2020

MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease

1 reference

12 December 2020

Multiple-drug resistance in human cancer

1 reference

12 December 2020

Prognostic factors for favorable outcome in disseminated germ cell tumors

1 reference

12 December 2020

Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro

1 reference

12 December 2020

Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine.

1 reference

12 December 2020

Chronic oral etoposide

1 reference

12 December 2020

A phase I-II study of cytosine arabinoside, daunorubicin, and VP16-213 in adult patients with acute non-lymphocytic leukemia

1 reference

12 December 2020

Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide

1 reference

12 December 2020

Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside)

1 reference

12 December 2020

Treatment of relapsed and refractory acute myeloid leukemia in adults

1 reference

12 December 2020

EVA treatment for recurrent or unresponsive Hodgkin's disease.

1 reference

12 December 2020

Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada

1 reference

12 December 2020

Idarubicin alone or in combination with cytarabine and etoposide (3 + 3 + 5 protocol) in acute non-lymphoblastic leukaemia

1 reference

12 December 2020

Chemotherapy of small cell carcinoma of the lung with V. P. 16–213

1 reference

12 December 2020

Differentiation of human variant small cell lung cancer cell lines to a classic morphology by retinoic acid.

1 reference

12 December 2020

Etoposide as a single agent in relapsed advanced lymphomas. A phase II study.

1 reference

12 December 2020

Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Results of a prospective randomized FONICAP trial. Italian Lung Cancer Task Force

1 reference

12 December 2020

Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial

1 reference

12 December 2020

MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease

1 reference

12 December 2020

VP-16–213 salvage therapy for refractory germinal neoplasms

1 reference

12 December 2020

Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of

1 reference

12 December 2020

Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol

1 reference

12 December 2020

Cisplatin, doxorubicin, cyclophosphamide, and etoposide combination chemotherapy for small-cell lung cancer

1 reference

12 December 2020

Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin

1 reference

12 December 2020

Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer

1 reference

12 December 2020

Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure

1 reference

12 December 2020

Phase II trial of cisplatin and etoposide in children with advanced soft tissue sarcoma: a report from the Italian Cooperative Rhabdomyosarcoma Group.

1 reference

12 December 2020

Ewing's sarcoma: current status of diagnosis and treatment

1 reference

12 December 2020

Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia.

1 reference

12 December 2020

Activity of the epipodophyllotoxin VP-16 in the treatment of combination chemotherapy-resistant non-Hodgkin lymphoma

1 reference

12 December 2020

VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer

1 reference

12 December 2020

The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data

1 reference

12 December 2020

Epipodophylin derivative (VP 16-23) in malignant teratomas and choriocarcinomas

1 reference

12 December 2020

Phase II study of oral VP-16-213 in small cell lung cancer

1 reference

12 December 2020

Expression of a multidrug-resistance gene in human tumors and tissues

1 reference

12 December 2020

Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse

1 reference

12 December 2020

CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease

1 reference

12 December 2020

High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer--a phase II study in elderly patients or patients with cardiac risk

1 reference

12 December 2020

Ifosfamide in refractory male germ cell tumors

1 reference

12 December 2020

Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study

1 reference

12 December 2020

High-dose etoposide and marrow transplantation

1 reference

12 December 2020

A phase II study of oral etoposide in elderly patients with small cell lung cancer

1 reference

12 December 2020

Current status of etoposide in the management of small cell lung cancer

1 reference

12 December 2020

Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein

1 reference

12 December 2020

Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs.

1 reference

12 December 2020

Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen

1 reference

12 December 2020

Doxorubicin, cyclophosphamide, etoposide and platinum, doxorubicin, cyclophosphamide and etoposide for small-cell carcinoma of the lung

1 reference

12 December 2020

Combination cyclophosphamide, Adriamycin, and vincristine rapidly alternating with combination cisplatin and VP-16 in treatment of small cell lung cancer

1 reference

12 December 2020

Etoposide (VP-16-213). Current status of an active anticancer drug

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00684875

1 reference

Dimensions Publication ID

22 September 2017

1021216034

0 references

Fatcat ID

release_nhvvxbsoojhndioiaghgdmxm3u

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nhvvxbsoojhndioiaghgdmxm3u

24 November 2022

mapped directly with Wikidata item

1 reference